Valuation: Modalis Therapeutics Corporation

Market Cap 3.3B 20.62M 18.58M 17.17M 15.52M 29.36M 1.93B 30.08M 206M 82M 1.04B 77.37M 75.72M P/E 2024
-3.57x
P/E 2025 -2.01x
Enterprise Value 483M 3.02M 2.73M 2.52M 2.28M 4.31M 284M 4.41M 30.18M 12.03M 152M 11.35M 11.11M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
91.76%
Yield 2024 *
-
Yield 2025 -
09-11 Exegenesis Bio and Modalis Therapeutics Corporation Collaborate To Advance MDL-201 For Duchenne Muscular Dystrophy CI
08-10 Modalis Therapeutics Corporation Reports Earnings Results for the Half Year Ended June 30, 2026 CI
06-12 Modalis Therapeutics Corporation announced that it has received ¥2.64 million in funding from Evolution Capital Management LLC CI
05-27 Modalis Therapeutics Corporation announced that it expects to receive ¥2.64 million in funding from Evolution Capital Management LLC CI
05-13 Modalis Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02-12 Modalis Therapeutics Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 CI
25/08/25 Modalis Therapeutics Corporation announced that it has received ¥3.072 million in funding from Evolution Capital Management LLC CI
07/08/25 Modalis Therapeutics Corporation announced that it expects to receive ¥3.072 million in funding from Evolution Capital Management LLC CI
07/07/25 Modalis Therapeutics Licenses Gene Therapy IP from Broad Institute for Muscular Dystrophy Treatment MT
16/06/25 Modalis Issues Restricted Stock to Subsidiary Employee Under Incentive Plan MT
09/06/25 SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy CI
01/05/25 Modalis Issues 21,900 Shares for Restricted Stock Remuneration MT
27/01/25 Modalis Therapeutics Secures Japanese Patent for Gene Therapy MT
1 day-6.90%
1 week+3.85%
Current month-3.57%
1 month-10.00%
3 months-18.18%
6 months-59.70%
Current year-51.79%
1 week 22
Extreme 22
29
1 month 22
Extreme 22
34
Current year 22
Extreme 22
83
1 year 22
Extreme 22
83
3 years 22
Extreme 22
203
5 years 22
Extreme 22
1,021
10 years 22
Extreme 22
4,070
Manager TitleAgeSince
Chief Executive Officer 57 01/01/2016
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 01/01/2016
Director/Board Member 68 01/01/2016
Director/Board Member 73 01/08/2018
Date Insider Type Main position Quantity % Market Cap. Importance
24/9/24 Others

Founder

10,000 0.0220%
24/9/24 Others

Founder

10,000 0.0220%
24/9/24 Others

Founder

6,000 0.0132%
Change 5-day change 1-year change 3-year change Capi.($)
-6.90%+3.85%-61.97%-78.05% 20.62M
-1.06%-0.07%+60.76%+68.61% 67.53B
+1.62%+9.07%+14.34%+93.35% 60.74B
+0.51%-0.77%+20.30%+98.81% 55.66B
-0.95%+11.17%+22.21%+110.93% 47.97B
-0.23%+4.07%+25.63%+40.08% 45.24B
-6.40%-9.51%+181.99%+816.79% 39.08B
+1.97%+3.50%+25.78%+50.98% 35.34B
-0.76%-2.89%+79.60%+56.33% 33.45B
+1.05%+9.77%-37.66%+408.42% 26.49B
Average -1.12%+2.68%+33.10%+166.63% 41B
Weighted average by Cap. -0.44%+1.64%+43.78%+168.55%

Financials

2024 2025
Net sales - -
Net income -1.32B -8.24M -7.43M -6.86M -6.2M -11.73M -773M -12.02M -82.22M -32.77M -414M -30.92M -30.26M -2.15B -13.46M -12.13M -11.21M -10.13M -19.17M -1.26B -19.65M -134M -53.55M -676M -50.52M -49.45M
Net Debt -3.58B -22.36M -20.16M -18.62M -16.84M -31.85M -2.1B -32.64M -223M -88.95M -1.12B -83.93M -82.15M -2.81B -17.59M -15.86M -14.65M -13.24M -25.05M -1.65B -25.67M -176M -69.97M -884M -66.02M -64.62M
Projected Income Statement - Annual - Modalis Therapeutics Corporation
Logo Modalis Therapeutics Corporation
Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.
Employees
-
Date Price Change Volume
12/11/26 JP¥27.00 -6.90% 914,900
11/11/26 JP¥29.00 0.00% 294,400
10/11/26 JP¥29.00 +11.54% 1,311,900
09/11/26 JP¥26.00 +8.33% 684,600
06/11/26 JP¥24.00 -7.69% 4,101,400
  1. Stock Market
  2. Stocks
  3. 4883 Stock